Human epidermal growth factor receptor bispecific ligand trap RB200: abrogation of collagen-induced arthritis in combination with tumour necrosis factor blockade
Arthritis Research & Therapy2011Vol. 13(5), pp. R161–R161
Citations Over Time
Luke Gompels, N. M. Malik, Leigh A. Madden, Jin Pei, Marc Feldmann, H. Michael Shepard, Ewa Paleolog
Abstract
The human pan-EGF receptor bispecific ligand trap RB200, when combined with low-dose etanercept, abrogates CIA, suggesting that inhibition of events downstream of EGF receptor activation, in combination with TNFα inhibitors, may hold promise as a future therapy for patients with RA.
Related Papers
- → Tumor necrosis factor (TNF) inhibitor therapy for rheumatoid arthritis(2008)37 cited
- → Switching between TNFα antagonists in rheumatoid arthritis: personal experience and review of the literature(2011)30 cited
- → Recent Advances in Anti-Tumour Necrosis Factor (TNF) Therapy in Rheumatoid Arthritis(1999)6 cited
- → TNF Inhibitors for Rheumatoid Arthritis(2000)2 cited
- Twice-Weekly Etanercept for Active Rheumatoid Arthritis(1999)